AR021406A1 - Un mutante del virus de la rabia recombinante, y una vacuna antirrabica con virus vivos atenuados - Google Patents
Un mutante del virus de la rabia recombinante, y una vacuna antirrabica con virus vivos atenuadosInfo
- Publication number
- AR021406A1 AR021406A1 ARP990106028A ARP990106028A AR021406A1 AR 021406 A1 AR021406 A1 AR 021406A1 AR P990106028 A ARP990106028 A AR P990106028A AR P990106028 A ARP990106028 A AR P990106028A AR 021406 A1 AR021406 A1 AR 021406A1
- Authority
- AR
- Argentina
- Prior art keywords
- virus
- codon
- recombinant
- vaccine
- antirrabic
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title 1
- 108020004705 Codon Proteins 0.000 abstract 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 abstract 2
- 102000003886 Glycoproteins Human genes 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 2
- 241000711798 Rabies lyssavirus Species 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 229910052786 argon Inorganic materials 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960003127 rabies vaccine Drugs 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Mutantes del virus de la rabia recombinante, que comprenden una mutacion en el genoma viral, por lo que dicha mutacion comprende por lo menos unasustitucion del codon Arg333 en el gen que codifica la proteína G, con un codon que difiere en tresnucle otidos con respecto al mencionado codon Arg333. Estosmutantes del virus de la rabia tienen una glucoproteína G que comprende un aminoácido en la posicion 333, que se codifica por un codon que difiere en los tresnucleotidos con respecto alcodon Arg e n la posicion 333 del aminoácido en la glucoproteína del virus parental. Los citados mutantes del virus de la rabiarecombinante son estables y no patogenos en los animales inmunocompetentes y son adecuados para emplear en una vacunaantirrábica con v irus vivos atenuados.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98204001 | 1998-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021406A1 true AR021406A1 (es) | 2002-07-17 |
Family
ID=8234392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106028A AR021406A1 (es) | 1998-11-27 | 1999-11-26 | Un mutante del virus de la rabia recombinante, y una vacuna antirrabica con virus vivos atenuados |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6719981B1 (es) |
| EP (1) | EP1131414B1 (es) |
| AR (1) | AR021406A1 (es) |
| AT (1) | ATE356202T1 (es) |
| AU (1) | AU1386100A (es) |
| BR (1) | BR9915703B1 (es) |
| CA (1) | CA2352231C (es) |
| CY (1) | CY1106570T1 (es) |
| DE (1) | DE69935445T2 (es) |
| DK (1) | DK1131414T3 (es) |
| ES (1) | ES2283150T3 (es) |
| ID (1) | ID28968A (es) |
| IL (2) | IL143149A0 (es) |
| PT (1) | PT1131414E (es) |
| TR (1) | TR200101445T2 (es) |
| WO (1) | WO2000032755A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1253197B1 (en) * | 2001-04-23 | 2006-01-25 | Akzo Nobel N.V. | Attenuated recombinant rabies virus and live vaccines thereof |
| HUP0500722A2 (hu) | 2001-07-20 | 2005-11-28 | The University of Georgia Research Foundation, Inc@Á | Attenuált veszettség vírus, a veszettség elleni vakcináláshoz és a központi idegrendszer génterápiájához egy nukleoprotein mutációval a foszforilezés helyén |
| EP1945780B1 (en) | 2005-10-14 | 2015-09-16 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Rabies virus vector systems and compositions and methods thereof |
| US7785874B2 (en) * | 2007-01-11 | 2010-08-31 | The Salk Institute For Biological Studies | Compositions and methods for monosynaptic transport |
| TW200907058A (en) | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| US10849975B2 (en) | 2011-02-03 | 2020-12-01 | Thomas Jefferson University | Multivalent vaccines for rabies virus and filoviruses |
| CN103865889B (zh) * | 2014-04-03 | 2015-02-25 | 深圳市卫光生物制品股份有限公司 | 狂犬病病毒ctn鸡胚细胞适应株 |
| EP4104854A3 (en) | 2016-04-04 | 2023-03-08 | The United States of America as represented by the Secretary of the Department of Health and Human Services | Multivalent vaccines for rabies virus and coronaviruses |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2580176B1 (fr) * | 1985-04-12 | 1988-02-26 | Centre Nat Rech Scient | Vaccin antirabique avirulent |
| FR2633832B1 (fr) * | 1988-07-05 | 1991-05-31 | Virbac | Vaccin antirabique avirulent |
| FR2693655B1 (fr) * | 1992-07-20 | 1994-10-14 | Virbac | Vaccin antirabique avirulent. |
| SE0002498D0 (sv) | 2000-07-03 | 2000-07-03 | Stefan Schwartz | Papillomavirus vaccine |
| US20050247051A1 (en) | 2001-12-10 | 2005-11-10 | Donaldson Company, Inc. | Exhaust treatment control system for an internal combustion engine |
| DE102004009653A1 (de) | 2004-02-27 | 2005-09-22 | Cycos Ag | Kommunikationsserver und Verfahren zum Aufbau und Betrieb einer Konferenz-Kommunikationsverbindung |
-
1999
- 1999-11-19 ID IDW00200101139A patent/ID28968A/id unknown
- 1999-11-19 BR BRPI9915703-9A patent/BR9915703B1/pt not_active IP Right Cessation
- 1999-11-19 US US09/856,653 patent/US6719981B1/en not_active Expired - Lifetime
- 1999-11-19 AU AU13861/00A patent/AU1386100A/en not_active Abandoned
- 1999-11-19 DK DK99973064T patent/DK1131414T3/da active
- 1999-11-19 WO PCT/EP1999/009101 patent/WO2000032755A1/en active IP Right Grant
- 1999-11-19 TR TR2001/01445T patent/TR200101445T2/xx unknown
- 1999-11-19 IL IL14314999A patent/IL143149A0/xx active IP Right Grant
- 1999-11-19 AT AT99973064T patent/ATE356202T1/de active
- 1999-11-19 ES ES99973064T patent/ES2283150T3/es not_active Expired - Lifetime
- 1999-11-19 PT PT99973064T patent/PT1131414E/pt unknown
- 1999-11-19 DE DE69935445T patent/DE69935445T2/de not_active Expired - Lifetime
- 1999-11-19 EP EP99973064A patent/EP1131414B1/en not_active Expired - Lifetime
- 1999-11-19 CA CA2352231A patent/CA2352231C/en not_active Expired - Fee Related
- 1999-11-26 AR ARP990106028A patent/AR021406A1/es not_active Application Discontinuation
-
2001
- 2001-05-14 IL IL143149A patent/IL143149A/en not_active IP Right Cessation
-
2007
- 2007-05-09 CY CY20071100622T patent/CY1106570T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL143149A (en) | 2007-12-03 |
| CY1106570T1 (el) | 2012-01-25 |
| DE69935445D1 (de) | 2007-04-19 |
| DK1131414T3 (da) | 2007-06-18 |
| WO2000032755A1 (en) | 2000-06-08 |
| US6719981B1 (en) | 2004-04-13 |
| PT1131414E (pt) | 2007-04-30 |
| BR9915703A (pt) | 2001-08-14 |
| ES2283150T3 (es) | 2007-10-16 |
| ID28968A (id) | 2001-07-19 |
| ATE356202T1 (de) | 2007-03-15 |
| BR9915703B1 (pt) | 2012-09-04 |
| EP1131414B1 (en) | 2007-03-07 |
| EP1131414A1 (en) | 2001-09-12 |
| IL143149A0 (en) | 2002-04-21 |
| TR200101445T2 (tr) | 2001-10-22 |
| AU1386100A (en) | 2000-06-19 |
| DE69935445T2 (de) | 2007-11-29 |
| CA2352231C (en) | 2010-06-01 |
| CA2352231A1 (en) | 2000-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2140418T3 (es) | Flavivirus quimericos y/o flavivirus de crecimiento restringido. | |
| ES2256323T5 (es) | Variante del virus Vaccinia Ankara Modificado | |
| Ramsburg et al. | A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals | |
| JP5166505B2 (ja) | 組換えｍｖａおよびその生産方法 | |
| ATE526411T1 (de) | Avirulente, immunogene flavivirus-chimäre | |
| CA2334857A1 (en) | Interferon inducing genetically engineered attenuated viruses | |
| RU2008102654A (ru) | Инактивированные химерные вакцины и связанные с ними способы применения | |
| CY1106570T1 (el) | Σταθερες, εξασθενημενες μεταλλαγμενες μορφες ιου λυσσας και ζωντανια εμβολια αυτων | |
| US11534417B2 (en) | Enhanced expression of RNA vectors | |
| WO2002072802A3 (en) | Live attenuated strains of prrs virus | |
| JPWO2005054451A1 (ja) | 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター | |
| CA2430115A1 (en) | Recombinant rsv virus expression systems and vaccines | |
| Yang et al. | A single immunization with recombinant rabies virus (ERAG3G) confers complete protection against rabies in mice | |
| Li et al. | Generation of an attenuated Tiantan vaccinia virus strain by deletion of multiple genes | |
| AU2018275790B2 (en) | Genetically attenuated nucleic acid vaccine | |
| KR20150137085A (ko) | 안정화된 ｆｍｄｖ 캡시드 | |
| Wong et al. | Systemic toll-like receptor ligation and selective killing of dendritic cell subsets fail to dissect priming pathways for anti-vaccinia virus CD8+ T cells | |
| Megret et al. | Immunopotentiation of the antibody response against influenza HA with apoptotic bodies generated by rabies virus G-ERA protein-driven apoptosis | |
| Palese et al. | Learning from our foes: a novel vaccine concept for influenza virus | |
| ATE453708T1 (de) | Impfstoff gegen west nile virus | |
| BR0201366A (pt) | Vìrus da raiva mutante recombinante, mutante, vìrus da raiva recombinante, e, vacina anti-raiva viva atenuada | |
| AR031599A1 (es) | Vacunas para el virus herpes equino tipo 1: virus que hospeda mutaciones dentro del gen inmediato precoz | |
| CA2351010A1 (en) | A broad spectrum infectious bursal disease virus vaccine | |
| TR200102168T2 (tr) | BHV-1 geni silinmiş virüs aşısı. | |
| Ambati et al. | Corrigendum: MSH3 Homology and Potential Recombination Link to SARS-CoV-2 Furin Cleavage Site |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |